South Africa's patent reform delay costs patients access

In 2012, a document surfaced in South Africa that became known as the 'Pharmagate' memo. It revealed that pharmaceutical industry representatives had lobbied government officials to block changes to patent law that would have made medicines cheaper and more accessible, according to Health-e News. More than a decade later, the Patent Amendment Bill remains unpassed.

The Bill, if enacted, would allow South Africa to use legal mechanisms known as 'flexibilities' under the international TRIPS Agreement. These provisions permit countries to produce or import lower-cost generic versions of patented medicines in the interest of public health, Health-e reported.

What the delay means in practice

South Africa carries one of the world's highest burdens of HIV, tuberculosis, and cancer. Health-e noted that the current patent framework keeps newer medicines under monopoly pricing for extended periods, placing them beyond reach for the public health system and for patients who pay out of pocket.

For people with albinism specifically, access to dermatological treatments and sun-protective products sits within the same procurement system that the Bill would affect. Affordable access to medical-grade sunscreen and skin cancer treatment — conditions that disproportionately affect people with albinism in high-UV environments — depends in part on whether government procurement can negotiate on price.

Twelve years is the span Health-e cited between the Pharmagate exposure and the present absence of legislative action.

What advocates are asking for

Health-e called on the South African government to table the Patent Amendment Bill without further delay. The publication framed the reform as a matter of protecting the constitutional right to healthcare, a right enshrined in Section 27 of South Africa's Constitution.

Civil society organisations have consistently supported the Bill, arguing that patent monopolies on essential medicines contradict the state's obligation to progressively realise access to health, according to Health-e. Opponents of reform, primarily originating from the pharmaceutical industry, have argued that weakening patent protections would reduce incentives for research and development investment in the country.

Health-e's reporting did not indicate a current parliamentary timeline for the Bill's introduction.

The connection between patent law and lived health outcomes is rarely visible in daily life. For people with albinism managing chronic sun damage, that distance between policy and pharmacy shelf is one that gets crossed — or does not — every time a prescription is written.